RESUMO
The purpose: to ascertain possible cardioprotective effect of Sodium-L-arginine Succinate in case of myocardial lesions caused by Doxorubicin in rats. Methods. The effectiveness of the drug was assessed by morphometric and biochemical changes reflecting peroxidation intensity and structural and functional changes in myocardium. Results. Sodium-L-arginine Succinate used for the treatment and prophylaxis of antracyclic cardiomyopathy was demonstrated to decrease Doxorubicin effects lessening cardiomyocytal destruction and the left ventricular dysfunction with myocardial hypertrophy.
Assuntos
Arginina/farmacologia , Cardiomiopatias , Doxorrubicina/efeitos adversos , Succinatos/farmacologia , Vasodilatadores/farmacologia , Animais , Cardiomiopatias/induzido quimicamente , Cardiomiopatias/prevenção & controle , Cardiotoxicidade/tratamento farmacológico , Doxorrubicina/farmacologia , Masculino , RatosRESUMO
Age-dependent angiogenesis intensity changes have been studied in transgenic HER-2/neu (FBV/N) mice characteristic of breast tumors' high incidence with hyperexpression of HER-2/neu. Concentration of vascular endothelial growth factor, insulin-dependent growth factor 1, nitrogen monoxide, tissue plasminogen activator and type 1 plasminogen activator inhibitor were assessed by means of immune-enzyme assay. The results testify to angiogenesis processes activation side by side with aging and growth of the tumors. Maximum manifestation of these disturbances (growth factors' blood concentrations increase and endotheliocytes' functional activity inhibition) has been revealed in 6-month-old mice during neoplasma maximum intensive and aggressive growth period.
Assuntos
Adenocarcinoma/sangue , Envelhecimento/sangue , Biomarcadores Tumorais/sangue , Neoplasias Mamárias Animais/sangue , Neovascularização Patológica/sangue , Receptor ErbB-2/sangue , Adenocarcinoma/irrigação sanguínea , Envelhecimento/metabolismo , Envelhecimento/patologia , Animais , Feminino , Fator de Crescimento Insulin-Like I/metabolismo , Neoplasias Mamárias Animais/irrigação sanguínea , Neoplasias Mamárias Experimentais , Camundongos , Camundongos Endogâmicos , Camundongos Transgênicos , Óxido Nítrico/sangue , Inibidor 1 de Ativador de Plasminogênio/sangue , Ativador de Plasminogênio Tecidual/sangue , Fator A de Crescimento do Endotélio Vascular/sangueRESUMO
AIM: To explore the endogenous and pharmacological activation of neurotrophic mechanisms in a model of brain ischemic lesion in rats. MATERIAL AND METHODS: The study was performed on 170 male albino rats (195-205 g). The model of ischemic stroke was accomplished by the electrocoagulation of the proximal segment of the left middle cerebral artery and simultaneous permanent ligation of the left common carotid artery. RESULTS AND CONCLUSION: The evaluation of NSE, NO, VEGF, NGF levels in the brain cytoplasmic lysate and plasma showed the delayed activation of neurotrophic mechanisms in astrocytes accompanied by a decrease in delayed alteration of neurons. The use of cytoflavin in the treatment of stroke was accompanied by the earlier and more intense activation of neurotrophic mechanisms in astrocytes, delayed activation of neurotrophic mechanisms in endothelial cells, which promoted neuroprotection in acute ischemic stroke.
Assuntos
Mononucleotídeo de Flavina/uso terapêutico , Inosina Difosfato/uso terapêutico , Fatores de Crescimento Neural/metabolismo , Fármacos Neuroprotetores/uso terapêutico , Niacinamida/uso terapêutico , Óxido Nítrico/metabolismo , Fosfopiruvato Hidratase/metabolismo , Acidente Vascular Cerebral/tratamento farmacológico , Acidente Vascular Cerebral/metabolismo , Succinatos/uso terapêutico , Fator A de Crescimento do Endotélio Vascular/metabolismo , Animais , Astrócitos/efeitos dos fármacos , Astrócitos/metabolismo , Modelos Animais de Doenças , Combinação de Medicamentos , Mononucleotídeo de Flavina/farmacologia , Inosina Difosfato/farmacologia , Masculino , Fatores de Crescimento Neural/análise , Fatores de Crescimento Neural/sangue , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Fármacos Neuroprotetores/farmacologia , Niacinamida/farmacologia , Óxido Nítrico/análise , Óxido Nítrico/sangue , Fosfopiruvato Hidratase/análise , Fosfopiruvato Hidratase/sangue , Ratos , Succinatos/farmacologia , Fator A de Crescimento do Endotélio Vascular/análise , Fator A de Crescimento do Endotélio Vascular/sangueRESUMO
108 albino male rats were used in two experimental rat models reproducing urolithiasis for the assessment of metabolic drug medicine Remaxol nephroprotective effect upon the development of this disease. "Ethyleneglycol" model consisted of adding 1% ethylene glycol solution in drinking water for 37 days and "fructose-induced" one--of adding 10% fructose solution in drinking water for the same period. Therapy included a 10-day course of daily i.v. injections of Remaxol (14 ml/kg). Both experimental models were successful in producing urolithiasis with considerable disturbances in the structure and functioning of kidneys up to revealing microconcrement formation. The "ethyleneglycol" model proved to cause maximum changes while the "Fructose-induced" model--only moderate ones. Metabolic correction of these changes was successful in nephroprotection effectively normalizing kidney functions and the total protein concentration, eliminating hyperglycemia and reducing creatinine and urea blood plasma concentration in both rat experimental models.
